Crinetics Pharmaceuticals, Inc. (CRNX)
84.84
-0.01
(-0.01%)
USD |
NASDAQ |
Aug 28, 16:00
84.97
+0.13
(+0.15%)
Pre-Market: 20:00
Crinetics Pharmaceuticals Cash from Operations (Quarterly) : -94.19M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -94.19M |
| March 31, 2026 | -124.70M |
| December 31, 2025 | -92.90M |
| September 30, 2025 | -110.72M |
| June 30, 2025 | -85.85M |
| March 31, 2025 | -88.45M |
| December 31, 2024 | -64.67M |
| September 30, 2024 | -62.82M |
| June 30, 2024 | -45.62M |
| March 31, 2024 | -52.86M |
| December 31, 2023 | -38.52M |
| September 30, 2023 | -41.34M |
| June 30, 2023 | -45.74M |
| March 31, 2023 | -40.72M |
| December 31, 2022 | -35.21M |
| September 30, 2022 | -38.48M |
| June 30, 2022 | -27.98M |
| March 31, 2022 | -13.54M |
| Date | Value |
|---|---|
| December 31, 2021 | -22.90M |
| September 30, 2021 | -25.67M |
| June 30, 2021 | -19.95M |
| March 31, 2021 | -20.07M |
| December 31, 2020 | -15.94M |
| September 30, 2020 | -18.00M |
| June 30, 2020 | -15.86M |
| March 31, 2020 | -12.23M |
| December 31, 2019 | -13.45M |
| September 30, 2019 | -13.61M |
| June 30, 2019 | -12.57M |
| March 31, 2019 | -6.759M |
| December 31, 2018 | -6.009M |
| September 30, 2018 | -5.693M |
| June 30, 2018 | -4.35M |
| March 31, 2018 | -3.407M |
| December 31, 2017 | -2.511M |
| September 30, 2017 | -2.443M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 1.125B |
| Johnson & Johnson | 8.616B |
| Eli Lilly & Co. | 10.69B |
| Bristol Myers Squibb Co. | 3.393B |
| Corcept Therapeutics, Inc. | 33.54M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 26.29M |
| Cash from Financing (Quarterly) | 8.925M |
| Free Cash Flow | -425.18M |
| Free Cash Flow Per Share (Quarterly) | -0.8973 |
| Free Cash Flow to Equity (Quarterly) | -94.05M |
| Free Cash Flow to Firm (Quarterly) | -94.71M |
| Free Cash Flow Yield | -5.02% |